Shots:

• The approval is based on REFLECTIONS B327-02 study assessing Trazimera in 500 patients with HER2 overexpressing breast cancer & m- gastric/GEJ adenocarcinoma across 20 countries
• REFLECTIONS B327-02 study demonstrated a high degree of similarity & no clinical differences b/w Trazimera & Herceptin
• Trazimera (trastuzumab-biosimilar) is a HER2 receptor antagonist biosimilar to Herceptin and has received EU’s approval in Jul'18 for the same indication

Ref: Pfizer | Image: Pfizer Centreone